PAVmed (PAVM) Q2 2026 earnings summary

Executive summary

• Tangible progress across Lucid, Veris, and PortIO, with Lucid advancing reimbursement and commercialization, Veris accelerating rollout at OSU, and PortIO achieving positive first-in-human results; Octeris continues technical development and clinical validation planning.

• Revenue from management fees and subscriptions remained stable, with Veris Health and Lucid Diagnostics as key contributors; Lucid processed 2,770 EsoGuard tests and secured its first laboratory benefit manager coverage policy.

• Commercial expansion included a VA contract for EsoGuard, strategic partnerships for Veris, and new device licensing; $30M Series D Preferred Stock financing and recapitalization completed.

• Operating as a commercial-stage life sciences company, the group focuses on advancing healthcare technologies in diagnostics, digital health, and medical devices.

• Developed a health economic model for EsoGuard, demonstrating improved outcomes and cost-effectiveness.

Financial highlights

• Q2 2026 revenue was $1.5 million, with management fee revenue at $3.2 million; revenue from other segments remained flat or minimal.

• GAAP net loss for Q2 ranged from $5.5 million to $14.7 million, with non-GAAP net loss as low as $1.7 million; net loss attributable to common stockholders for six months was $12.5 million.

• Cash at June 30, 2026, was $3.8 million for the parent and $33.4 million for Lucid; cash used in operations was $5.3 million for six months.

• Completed $30 million Series D Preferred Stock offering, issued $15 million senior secured note, and raised $7.6 million net proceeds after redemptions and refinancing.

• Non-GAAP operating expenses for Q2 2026 were $6.1–$6.3 million, mainly due to Veris R&D.

Outlook and guidance

• Awaiting positive Medicare draft coverage for Lucid’s EsoGuard; positioned for expanded commercial opportunities.

• Veris targets early 2027 for FDA 510(k) submission and aims to onboard 1,000 patients at OSU within the first year.

• PortIO expects to submit an FDA pre-submission meeting request in Q4 2026, with potential regulatory pathway shift to 510K.

• Octeris preparing for clinical validation at USC/UNC, with IRB approval and FDA pre-submission draft completed.

• Management expects recurring losses and negative cash flows to continue, with substantial doubt about going concern status without additional capital.